Dammam Valley, an investment fund owned by the Imam Abdulrahman bin Faisal University in Saudi Arabia, has acquired a majority stake in direct-to-consumer clinical genetic testing startup Arcensus. Rostock, Germany-based Arcensus said that Dammam Valley and other undisclosed investors are making a “double-digit million euro” investment, without actually disclosing any […]
To read the rest of this article, you must be a subscriber. Click here to buy a subscription plan or Login here if you are already a subscriber.